The present invention generally relates to a set of early developmental reference data or “lineage scorecard” for stem cells, and methods, systems and kits to generate a lineage scorecard for predicting the functionality and suitability of stem cell lines. In some aspects, methods for generating a scorecard comprises measuring the gene expression of a plurality of early developmental genes, such as pluripotent, early ectoderm, early mesoderm and early endoderm genes to predict the pluripotency and differentiation potential of the stem cell line and its functionality and/or suitability for a desired use. In some embodiments, a reference scorecard can be compared with the test stem cell line scorecard to accurately predict the utility and/or identify specific characteristics of the stem cell line, e.g., to determine its suitability for downstream applications, e.g., therapeutic use, drug screening, toxicity assays, differentiation into a desired cell lineage, etc.

Methods for generating high-yield, high-purity cardiac fibroblasts are described. Differentiation methods comprising chemically defined culture conditions and methods for in vitro maintenance of human pluripotent stem cell-derived cardiac fibroblasts are also provided.

Disclosed herein are non-naturally existing novel platelet variants or platelet like cells (PLCs), extracellular vesicles (EVs), and derivatives thereof. Composition comprising the same and methods for treatment or prevention of diseases or disorders therewith is also disclosed.

The present disclosure provides a method for treating an inflammatory neurological disease comprising administering a population of cells enriched for STRO-1.sup.+ cells and/or progeny thereof and/or soluble factors derived therefrom.

Described herein is a method of treating a disorder, the method comprising: administering to a subject in need thereof a composition that contains a population of somatic stem cells that are 0.3-6.0 micrometers in size and CD9+, CD349+, CD133−, CD90−, CD34−, SSEA1+, SSEA4+, CD13+, or Stro1+, wherein the disorder is hair loss, osteoporosis, or a damaged tissue.

Methods, compositions and cells are provided that identify and isolate a population of adult non-embryonic progenitor cells having multilineage potential, physical diameters of about 2 μm to about 8 μm in size or about 4 μm to about 6 μm, and expressing at least one of the stem cell associated genes among Oct-4, KLF-4, Nanog, Sox-2, Rex-1, GDF-3 or Stella. Methods are also provided that identify and isolate populations, which are subsets or subpopulations of progenitor adult stem cells within the population of the adult stem cells which is a heterogeneous population, the methods including contacting the adult stem cells with a ligand specific for at least one of: CD99, tetraspan, ICAM4, full-length MUC1, and truncated MUC1 receptor, in which a presence of a surface protein on the cells that bind to the ligand identifies the population which is the subset of the differentiated progenitor adult stem cells.

The invention relates to a bioreactor cell culture system comprising a closed chamber containing a plurality of suspended cell microcompartments, wherein the microcompartments each comprise an outer hydrogel layer providing a cavity containing a set of self-organized cells and extracellular matrix or an extracellular matrix substitute. The invention further relates to the use of such bioreactors to produce cells and/or organoids, and/or molecules and/or complex molecular assemblies.

Use of a transforming growth factor beta (TGF-β) signalling inhibitor for producing a population of brown adipocytes in vitro.

The object of the present invention is to improve the post-transplantation engraftment rate of cardiomyocytes that have been purified to such an extent that they are free from non-cardiomyocytes and any components derived from other species. To solve this problem, the present inventors studied the possibility of constructing cell masses from the purified cardiomyocytes. As a result, they revealed that the stated problem could be solved by providing a method of preparing cell masses of cardiomyocytes derived from pluripotent stem cells, characterized in that cell masses of aggregated cells containing cardiomyocytes that had been differentiated and induced from pluripotent stem cells were dispersed to single cells to thereby obtain purified cardiomyocytes, which were then cultured in a culture medium under serum-free conditions so that they were reaggregated.

Provided is an information processing apparatus including an acquiring unit that acquires cell information indicating a state of a cell from production of a pluripotent stem cell to differentiation of the pluripotent stem cell into a specific differentiated cell by differentiation induction, and process history information indicating a history of a processing process for obtaining the differentiated cell, and a deriving unit that derives differentiation potency information indicating differentiation potency of the pluripotent stem cell based on the cell information and the process history information which are acquired by the acquiring unit.